Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Benefit-Cost Analysis | Costing Methods | Global | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
ReportPublication 2017DCP3: Injury Prevention and Environmental Health
This report from the World Bank is the seventh volume of the Disease Control Priorities, …
This report from the World Bank is the seventh volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on injury prevention and environmental health. The burden of death and disability resulting from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, and climate and pollution falls disproportionately on low- and middle- income countries. This report examines risk factors and offers an economic analysis of platforms to deliver cost-effective interventions to prevent…
Benefit-Cost Analysis | Costing Methods | Global | Environmental Health | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Injuries/Accidents | Policy/Regulation | Global Governance | Climate/Environment | Culture/Society | Economics/Finance | Health/Medicine -
ReportPublication 2016Economics of Tobacco and Tobacco Control
This report examines the current research and evidence base surrounding the economics of tobacco control—including tobacco …
This report examines the current research and evidence base surrounding the economics of tobacco control—including tobacco use, tobacco growing, manufacturing and trade, tobacco product taxes and prices, and tobacco control policies and other interventions to reduce tobacco use and its consequences. The report was co-produced by the National Cancer Institute and the World Health Organization and is intended to inform tobacco prevention and control programs and policies in countries around the world. There are 17 chapters which can be…
Benefit-Cost Analysis | Costing Methods | Global | Chronic Disease/Risk | Policy/Regulation | Food/Agriculture | Government/Law | Health/Medicine -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Costing Methods | Global | Chronic Disease/Risk | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2021Global Costs, Health Benefits, & Economic Benefits of Scaling Up Treatment and Imaging Modalities for Survival of 11 Cancers
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging …
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival in 200 countries/territories for patients diagnosed with one of 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). Using a microsimulation model of global cancer survival, the paper evaluated the costs and health and economic benefits of scaling up packages of treatment (chemotherapy, surgery, radiotherapy, and targeted…
Benefit-Cost Analysis | Global | Chronic Disease/Risk | Priority Setting/Ethics | Health Outcomes | Microsimulation | Health Systems -
BookPublication 2019Non-Communicable Disease Prevention: Best Buys, Wasted Buys, Contestable Buys
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these …
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these deaths occur in low- and middle-income countries. This book provides practical guidelines and lessons learned through real-world case studies. It is intended to be informative to NCD program managers, policy officers and decision-makers in low- and middle-income countries, who need to comparatively assess interventions for the prevention and control of NCDs.The authors emphasize the importance of context in NCD control…
Technology Assessment | Global | Chronic Disease/Risk | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Policy/Regulation | Health/Medicine -
ReportPublication 2017DCP3: Cardiovascular, Respiratory, and Related Disorders
This report from the World Bank is the fifth volume of the Disease Control Priorities, …
This report from the World Bank is the fifth volume of the Disease Control Priorities, Third Edition (DCP3) series. It addresses the disease burden of cardiovascular, respiratory, and related disorders (CVRDs), which account for more than half of global adult deaths, mostly in low- and middle-income countries. While CVRDs are mostly preventable or can be treated to reduce morbidity, such interventions are costly and require greater capacity to detect and treat early. When combined with…
Costing Methods | Global | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Global Governance | Climate/Environment | Health/Medicine -
ReportPublication 2015DCP3: Cancer
This report from the World Bank is the third volume of the Disease Control Priorities, …
This report from the World Bank is the third volume of the Disease Control Priorities, Third Edition (DCP3) series. It presents data on the complex patterns of cancer incidence and deaths globally, and offers evidence on effective measures to control cancers. This report identifies settings in which cancer treatment may be ineffective or wasteful, and offers alternative cancer care packages that are cost-effective and better suited to low-resource environments. The Disease Control Priorities Network (DCP)…
Costing Methods | Global | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Global Governance | Economics/Finance | Health/Medicine -
ReviewPublication 2018Primary & Secondary Prevention Interventions for Cardiovascular Disease in LMIC's
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for …
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for the money, the authors conducted a systematic review, including 50 studies. Included studies were those that reported full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. The majority of the studies were of modelled evaluations, with significant heterogeneity in methods. Most of the economic evaluations evaluated were…
Costing Methods | Global | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Health/Medicine